NCT05112549: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Leptomeningeal disease
Additional Notes: Patients must have primary tissue available for analysis

Comments are closed.

Up ↑